View in EDS

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Saved in:
Bibliographic Details
Title: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Authors: Li X; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland., Benegiamo G; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland., Vijayakumar A; OrsoBio, Menlo Park, CA, USA., Sroda N; OrsoBio, Menlo Park, CA, USA., Kimura M; Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA., Huss RS; OrsoBio, Menlo Park, CA, USA., Weng S; OrsoBio, Menlo Park, CA, USA., Murakami E; OrsoBio, Menlo Park, CA, USA., Kirby BJ; OrsoBio, Menlo Park, CA, USA., von Alvensleben GVG; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland., Kremoser C; WM Therapeutics, Heidelberg, Germany., Gane EJ; New Zealand Clinical Research, University of Auckland, Auckland, New Zealand., Takebe T; Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), and Division of Stem Cell and Organoid Medicine, The University of Osaka, Suita, Japan., Myers RP; OrsoBio, Menlo Park, CA, USA., Subramanian GM; OrsoBio, Menlo Park, CA, USA. mani@orsobio.com., Auwerx J; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. admin.auwerx@epfl.ch.
Source: Nature medicine [Nat Med] 2026 Mar; Vol. 32 (3), pp. 883-893. Date of Electronic Publication: 2026 Jan 16.
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41545590
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Benegiamo+G%22">Benegiamo G</searchLink>; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Vijayakumar+A%22">Vijayakumar A</searchLink>; OrsoBio, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sroda+N%22">Sroda N</searchLink>; OrsoBio, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kimura+M%22">Kimura M</searchLink>; Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.<br /><searchLink fieldCode="AU" term="%22Huss+RS%22">Huss RS</searchLink>; OrsoBio, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22Weng+S%22">Weng S</searchLink>; OrsoBio, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22Murakami+E%22">Murakami E</searchLink>; OrsoBio, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kirby+BJ%22">Kirby BJ</searchLink>; OrsoBio, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22von+Alvensleben+GVG%22">von Alvensleben GVG</searchLink>; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kremoser+C%22">Kremoser C</searchLink>; WM Therapeutics, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Gane+EJ%22">Gane EJ</searchLink>; New Zealand Clinical Research, University of Auckland, Auckland, New Zealand.<br /><searchLink fieldCode="AU" term="%22Takebe+T%22">Takebe T</searchLink>; Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), and Division of Stem Cell and Organoid Medicine, The University of Osaka, Suita, Japan.<br /><searchLink fieldCode="AU" term="%22Myers+RP%22">Myers RP</searchLink>; OrsoBio, Menlo Park, CA, USA.<br /><searchLink fieldCode="AU" term="%22Subramanian+GM%22">Subramanian GM</searchLink>; OrsoBio, Menlo Park, CA, USA. mani@orsobio.com.<br /><searchLink fieldCode="AU" term="%22Auwerx+J%22">Auwerx J</searchLink>; Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. admin.auwerx@epfl.ch.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2026 Mar; Vol. 32 (3), pp. 883-893. <i>Date of Electronic Publication: </i>2026 Jan 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41545590
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-025-04169-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 883
    Titles:
      – TitleFull: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Benegiamo G
      – PersonEntity:
          Name:
            NameFull: Vijayakumar A
      – PersonEntity:
          Name:
            NameFull: Sroda N
      – PersonEntity:
          Name:
            NameFull: Kimura M
      – PersonEntity:
          Name:
            NameFull: Huss RS
      – PersonEntity:
          Name:
            NameFull: Weng S
      – PersonEntity:
          Name:
            NameFull: Murakami E
      – PersonEntity:
          Name:
            NameFull: Kirby BJ
      – PersonEntity:
          Name:
            NameFull: von Alvensleben GVG
      – PersonEntity:
          Name:
            NameFull: Kremoser C
      – PersonEntity:
          Name:
            NameFull: Gane EJ
      – PersonEntity:
          Name:
            NameFull: Takebe T
      – PersonEntity:
          Name:
            NameFull: Myers RP
      – PersonEntity:
          Name:
            NameFull: Subramanian GM
      – PersonEntity:
          Name:
            NameFull: Auwerx J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2026 Mar
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 32
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1